<DOC>
	<DOCNO>NCT00202956</DOCNO>
	<brief_summary>The objective evaluate effect biomarkers safety BGS postmenopausal patient osteoporosis .</brief_summary>
	<brief_title>Safety Efficacy Study Bugusan ( BGS ) Treat Osteoporosis .</brief_title>
	<detailed_description>The objective evaluate effect biomarkers safety BGS postmenopausal patient osteoporosis study Randomized , Double Blind , Placebo-Controlled , Parallel Group .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<criteria>1 . Postmenopausal woman age 45 75 year natural menopause ≧ 6 month serum E2 value &lt; 20 pg/ml , serum FSH value ≧ 25 mIU/mL ; 2 . Patients bone mineral density ＜2.5 SD T score lumbar spine ( L2L4 ) ; 3 . All patient must sign informed consent form ( ICF ) prior trial . 1 . Any Xray film document substantial scoliosis , spinal secondary osteoporosis ; 2 . Any Xray film document bone fracture within 3 month prior trial . 3 . Medication estrogen , bisphosphonates , calcitonin , fluoride , glucocorticoid , ipriflavone intake within 3 week prior trial ; 4 . Use Chinese medicine within 2 week prior trial ; 5 . Patients significant renal function impairment ( Creatinine &gt; 2mg/dl ) liver function impairment ( AST ALT &gt; 2 x upper limit normal range ) ; 6 . Patients laboratory test abnormality , investigator ’ opinion might confound study ; 7 . Patients severe cardiac disease , e.g . unstable angina pectoris , myocardial infarction , congestive heart failure ( New York Heart Association Functional Classification III IV ) ; 8 . Patients life threaten disease ; 9 . Patients allergic composition Chinese medicine ; 10 . Significant concomitant disease medical history could interfere study judged investigator ;</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2005</verification_date>
</DOC>